These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 36726910)

  • 1. Venetoclax and Azacitidine in the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm Refractory to Conventional Therapy.
    Azad F; Zhang J; Miranda CJ; Gravina M
    Cureus; 2022 Dec; 14(12):e33109. PubMed ID: 36726910
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tagraxofusp followed by combined azacitidine and venetoclax in blastic plasmacytoid dendritic cell neoplasm: A case report and literature review.
    Samhouri Y; Ursu S; Dutton N; Tanvi V; Fazal S
    J Oncol Pharm Pract; 2021 Jun; 27(4):990-995. PubMed ID: 32847479
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Blastic Plasmacytoid Dendritic Cell Neoplasm.
    Jain A; Sweet K
    J Natl Compr Canc Netw; 2023 May; 21(5):515-521. PubMed ID: 37156483
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overcoming Tagraxofusp-Erzs Monotherapy Resistance in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) in a Real-World Clinical Setting.
    Dhakal P; Sy M; Sutamtewagul G; Mou E; Yu N; Pemmaraju N
    J Immunother Precis Oncol; 2024 Aug; 7(3):205-209. PubMed ID: 39219995
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relapse of tagraxofusp treated blastic plasmacytoid dendritic cell neoplasm with loss of CD123 expression.
    Gulati R; Abu-Salah A; Salous T; Nassiri M
    J Hematop; 2022 Mar; 15(1):35-39. PubMed ID: 38358597
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Foot gangrene following Tagraxofusp treatment for blastic plasmacytoid dendritic cell neoplasm: Case report.
    Sibai J; Chen R; Nabhani IA; Perusini MA; Sibai H
    EJHaem; 2022 Nov; 3(4):1374-1376. PubMed ID: 36467820
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN): focus on the use of tagraxofusp and clinical considerations.
    Pemmaraju N; Madanat YF; Rizzieri D; Fazal S; Rampal R; Mannis G; Wang ES; Foran J; Lane AA
    Leuk Lymphoma; 2024 May; 65(5):548-559. PubMed ID: 38391126
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel Therapeutic Approaches in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Era of Targeted Therapy.
    Wilson NR; Konopleva M; Khoury JD; Pemmaraju N
    Clin Lymphoma Myeloma Leuk; 2021 Nov; 21(11):734-740. PubMed ID: 34226167
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tagraxofusp in myeloid malignancies.
    Bruzzese A; Martino EA; Labanca C; Mendicino F; Lucia E; Olivito V; Neri A; Imovilli A; Morabito F; Vigna E; Gentile M
    Hematol Oncol; 2024 Jan; 42(1):e3234. PubMed ID: 37846131
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tagraxofusp, a novel CD123-directed cytotoxin to treat blastic plasmacytoid dendritic cell neoplasm.
    Tandon A; Zhang Y; Sokol L
    Drugs Today (Barc); 2019 Dec; 55(12):735-742. PubMed ID: 31942876
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent developments in the treatment of blastic plasmacytoid dendritic cell neoplasm.
    Economides MP; Konopleva M; Pemmaraju N
    Ther Adv Hematol; 2019; 10():2040620719874733. PubMed ID: 31579499
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Blastic Plasmacytoid Dendritic Cell Neoplasm in Long-Term Complete Remission After Venetoclax Monotherapy.
    Sasaki Y; Murai S; Shiozawa E; Yamochi T; Hattori N
    Cureus; 2024 Jan; 16(1):e52446. PubMed ID: 38371152
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tagraxofusp as treatment for patients with blastic plasmacytoid dendritic cell neoplasm.
    Lee SS; McCue D; Pemmaraju N
    Expert Rev Anticancer Ther; 2020 Jul; 20(7):543-550. PubMed ID: 32460559
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent Advances in the Biology and CD123-Directed Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm.
    Pemmaraju N; Deconinck E; Mehta P; Walker I; Herling M; Garnache-Ottou F; Gabarin N; Campbell CJV; Duell J; Moshe Y; Mughal T; Mohty M; Angelucci E
    Clin Lymphoma Myeloma Leuk; 2024 Apr; 24(4):e130-e137. PubMed ID: 38267355
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Venetoclax combined with azacitidine in blastic plasmacytoid dendritic cell neoplasm: a case report and comprehensive review on the current and future treatment.
    Wang X; Guo J; Liu Y; Zheng N; Xu S; Wu L; Yuan R; Xue L; Li J
    Front Med (Lausanne); 2024; 11():1425833. PubMed ID: 39086951
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low-dose venetoclax combined with azacitidine for blastic plasmacytoid dendritic cell neoplasm: a case report and literature review.
    Wang Q; Zhao Y; Zang X; Zhou G; Liu Y; Feng Q; Li X; Wang W; Dong X; Liu X; Peng J; Liu C
    Ann Hematol; 2024 Mar; 103(3):999-1005. PubMed ID: 38285081
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hyper-CVAD combined with Venetoclax for relapsed pediatric blastic plasmacytoid dendritic cell neoplasm (BPDCN): A case report and literature review.
    Abla D; Abboud MR; Noun D; Tarek N; Pemmaraju N
    Leuk Res Rep; 2022; 17():100313. PubMed ID: 35462725
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tagraxofusp for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): A Brief Report on Emerging Data.
    Beziat G; Ysebaert L
    Onco Targets Ther; 2020; 13():5199-5205. PubMed ID: 32606740
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tagraxofusp, a first-in-class CD123-targeted agent: Five-year postapproval comprehensive review of the literature.
    Jen WY; Konopleva M; Pemmaraju N
    Cancer; 2024 Jul; 130(13):2260-2271. PubMed ID: 38620053
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluating tagraxofusp for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN).
    Wilson NR; Pemmaraju N
    Expert Opin Pharmacother; 2022 Mar; 23(4):431-438. PubMed ID: 35060807
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.